Aflibercept solution for injection for treating wet age‑related macular degeneration

TA294 Macular degeneration (wet age-related) - aflibercept: review decision - July 2014 information

Appendix A - Decision paper presented to the Institute's Guidance Executive

Appendix A - Decision paper presented to the Institute's Guidance Executive (PDF 112 KB)

Review Proposal - May 2014 information

Appendix A: provisional matrix of stakeholders

Appendix A: provisional matrix of stakeholders (PDF 49 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive

Macular degeneration (wet age-related) - aflibercept (1st line): equality impact assessment - guidance review

Macular degeneration (wet age-related) - aflibercept (1st line): final appraisal determination

Macular degeneration (wet age-related) - aflibercept (1st line): final appraisal determination document

Macular degeneration (wet age-related) - aflibercept (1st line): final appraisal determination document (PDF 418 KB)

Macular degeneration (wet age-related) - aflibercept (1st line): evaluation report information

Macular degeneration (wet age-related) - aflibercept (1st line): response to comments on the draft scope and provisional matrix

Macular degeneration (wet age-related) - aflibercept (1st line): EIA - scoping

Macular degeneration (wet age-related) - aflibercept (1st line): final scope

Macular degeneration (wet age-related) - aflibercept (1st line): final matrix

Macular degeneration (wet age-related) - aflibercept (1st line): appendix C - provisional matrix (pre-referral) - September 2011

Macular degeneration (wet age-related) - aflibercept (1st line): appendix B (pre-referral) - draft scope for consultaton - September 2011